Transarterial injection of 131I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer

Journal of Nuclear Medicine

Volumn 50, Issue 6, 2009, Pages 871-877

  Marelli, Laura ^a   Shusang, Vibhakorn ^a   Buscombe, John R ^a   Cholongitas, Evangelos ^a   Stigliano, Rosa ^a   Davies, Neil ^a   Tibballs, Jonathan ^a   Patch, David ^a   Meyer, Tim ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

131I lipiodol; Chemoembolization; Embolization; Hepatocellular carcinoma; Portal vein thrombosis

Indexed keywords

CISPLATIN; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; IODINE RADIOISOTOPES; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PORTAL VEIN; PROGNOSIS; RETROSPECTIVE STUDIES; VENOUS THROMBOSIS;

EID: 66649096146     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.060558     Document Type: Article

References (29)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917. (Pubitemid 37518510)
2. Martins A, Cortez-Pinto H, Marques-Vidal P, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687. (Pubitemid 43994787)
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442. (Pubitemid 36152543)
4. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25. (Pubitemid 44900485)
5. 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer. 1995;76:2202-2210.
6. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med. 1994;35:1782-1787. (Pubitemid 24346799)
7. 131I-labeled- iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 1997;26:1156-1161.
8. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II - systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs. 2004;15:439-452. (Pubitemid 38736941)
9. Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer. 1996;73:877-881. (Pubitemid 26110156)
10. Carr BI. Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10(2, suppl 1):S107-S110. (Pubitemid 38240109)
11. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR. 2007;188:768-775. (Pubitemid 46303204)
12. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:1375-1382. (Pubitemid 47628904)
13. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (Therasphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol. 2006;94:572-586. (Pubitemid 44851918)
14. 90yttrium resin-microspheres. Eur Radiol. 2007;17:1320-1330.
15. 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:792-800.
16. 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81.
17. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
18. Bernal P, Raoul JL, Vidmar G, et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys. 2007;69:1448-1455. (Pubitemid 350116402)
19. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739. (Pubitemid 34607087)
20. Grasso A, Stigliano R, Morisco F, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation. 2006;81:1532-1541. (Pubitemid 43890890)
21. Ramacciato G, Mercantini P, Nigri GR, et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology. 2006;53:898-903. (Pubitemid 44851224)
22. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000;31:840-845.
23. Chung H, Kudo M, Takahashi S, et al. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona clinic liver cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23:445-452.
24. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000;89:2266-2273.
25. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338. (Pubitemid 29488775)
26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214. (Pubitemid 11167383)
27. Shusang V, Papadapala AM, Sternet K, et al. Comparison of RECIST criteria and residual vascularity in evaluating therapeutic criteria response to embolization of hepatocellular carcinoma [abstract]. J Hepatol. 2006;44(suppl):S109.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
29. Blokhuis TJ, van der Schaaf MC, van den Tol MP, Comans EF, Manoliu RA, van der Sijp JR. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol. 2004;241(suppl):93-97. (Pubitemid 40051456)